Bio-Thera Reveals Positive BAT8008 and BAT1308 Data for Lung Cancer Treatment at ESMO 2026

Bio-Thera Solutions Presents Promising Cancer Treatment Data at ESMO 2026

In a significant development for cancer treatment, Bio-Thera Solutions, a prominent biopharmaceutical company based in Guangzhou, China, has unveiled promising clinical data for its innovative drug combination at the 2026 European Society for Medical Oncology (ESMO) Congress. The focus of this presentation was on the combination of BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), and BAT1308, an anti-PD-1 monoclonal antibody, particularly for patients with non-small cell lung cancer (NSCLC).

During the event, Professor Shaodong Hong, representing Sun Yat-sen University Cancer Center, shared insights from the Phase 2 clinical trials involving 104 patients diagnosed with mutation-negative NSCLC. The findings revealed that the BAT8008 and BAT1308 combination achieved an objective response rate (ORR) of 61.2%, alongside a median progression-free survival (PFS) of 12.42 months. Particularly noteworthy was the non-squamous NSCLC subgroup, where the ORR rose to 65.2%; however, median PFS had yet to be reached at the time of reporting.

The results indicate a promising safety profile, consistent with what is already known about the individual drugs, without any new safety concerns surfacing during the trials. Shengfeng Li, the CEO of Bio-Thera Solutions, expressed optimism regarding the Phase 2 outcomes, emphasizing the potential of this combination therapy in addressing advanced non-small cell lung cancer, which remains a major public health issue globally.

Lung cancer continues to present significant treatment challenges, especially for advanced-stage NSCLC patients who lack actionable genomic alterations. The emergence of new treatment strategies, particularly those that can yield improved clinical outcomes while maintaining patient safety, is crucial within the oncology sector.

The TROP2-targeted ADCs represent an innovative therapeutic option that combines targeted tumor delivery with mechanisms that can influence the tumor microenvironment. This synergistic approach is further enhanced when combined with PD-1 blockade, creating a compelling rationale for clinical investigations in NSCLC. The data presented by Bio-Thera at ESMO 2026 supports the call for more exhaustive evaluations of this drug combination as a potential treatment pathway for NSCLC patients.

Bio-Thera Solutions is committed to advancing novel therapeutics aimed at treating various diseases, including cancer, autoimmune conditions, and cardiovascular issues. The company stands out for its next-generation antibody research and development endeavors, with more than 20 promising candidates currently undergoing clinical trials. This robust pipeline highlights the company's dedication to improving health outcomes for patients facing significant medical challenges.

The positive reception of Bio-Thera's data at a prominent international congress is indicative of a potential shift in treatment paradigms for NSCLC, as they continue their mission to tackle crucial unmet medical needs through cutting-edge biopharmaceutical innovation.

For additional information about Bio-Thera Solutions and their ongoing research endeavors, please visit their official website or follow them on social media platforms.